Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 4/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23077766 | 0.90 | MEN1 (0.46) | PTGER1PTGER4PTGER3PTGER2FFAR1 | |
| SCHEMBL27635346 | 0.87 | IAPP (0.44) | PTGER1PTGER4PTGER3PTGER2CTSG | |
| SCHEMBL4699564 | 0.81 | TAAR1 (0.55) | PTGER1PTGER4PTGER3PTGER2PARP1 | |
| SCHEMBL1000052 | 0.81 | PTGER1 (0.47) | PTGER1PTGER4PTGER3PTGER2PARP1 | |
| SCHEMBL89295 | 0.81 | KEAP1 (0.54) | PTGER1PTGER4PTGER3PTGER2PARP1 | |
| SCHEMBL10955474 | 0.81 | MTNR1A (0.43) | TAAR1 | |
| SCHEMBL6612012 | 0.80 | PTGER1 (0.50) | PTGER1PTGER4PTGER3PTGER2PARP1 | |
| SCHEMBL28142232 | 0.80 | PTGER1 (0.46) | PTGER1PTGER4PTGER3PTGER2PARP1 | |
| SCHEMBL6248978 | 0.80 | MMP2 (0.48) | PTGER1PTGER4PTGER3PTGER2PARP1 | |
| SCHEMBL1178702 | 0.79 | NPSR1 (0.48) | PTGER1PTGER4PTGER3PTGER2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| CN-102083803-B | Oxocyclic substituted carboxylic acid derivatives and their use | BAYER IP GMBH | 2015-02-18 | — | — | CN | disclosed |
| CN-102083803-A | Oxocyclic substituted carboxylic acid derivatives and their use | BAYER SCHERING PHARMA AG | 2011-06-01 | — | — | CN | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | PTGER1 631/4885PTGER4 840/4885PTGER3 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.